SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is generating intense market attention as traders bet on a short squeeze and potential industry-wide transformation following an executive order from the U.S. government regarding the expedited research and development of psychedelic therapies. The community is heavily focused on the stock's low float, aggressive institutional interest, and the belief that the company's GMP-compliant ibogaine supply chain positions it as a critical player in a rapidly expanding mental health sector.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile shares are facing significant downward pressure following an orbital insertion failure during a Blue Origin launch that resulted in the loss of a satellite. While the community is actively debating the reliability of launch partners and the impact on the companys ambitious deployment roadmap, long-term investors are focused on insurance coverage and existing manufacturing pipelines as key catalysts for a potential rebound.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending following a massive $2.8 billion acquisition of Serra Verde Group, a move the market views as a strategic play to become a dominant, non-Asian leader in the rare earth supply chain. While investors are debating the impacts of the associated share dilution, community sentiment is largely focused on the company's long-term potential to anchor the Western EV and defense infrastructure.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is currently trending as retail investors ramp up activity ahead of the upcoming AACR conference, where new data for its SLS009 platform will be presented. The community is actively debating the potential for a short squeeze fueled by heavy call option positioning and large-scale short interest, while long-term supporters remain focused on the clinical potential of the GPS trial.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is seeing intense trading activity and community speculation driven by the anticipation of Phase 2b data for rezpegaldesleukin in alopecia areata, which remains a key binary event for the company. While the community is actively debating the potential for a clinical breakthrough, a lucrative partnership, or a legal settlement with Eli Lilly, traders are closely monitoring price volatility ahead of these major upcoming catalysts.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing heightened investor attention driven by strong bullish sentiment surrounding its lead asset, CAN-2409, and anticipation of upcoming data releases at the American Urological Association annual meeting. The community is actively discussing the potential for a significant squeeze on high short interest, while supporters emphasize the company's robust balance sheet and long-term value potential in the oncology space.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as investors weigh strong steel shipment volumes and positive free cash flow expectations against ongoing geopolitical volatility and short-term earnings headwinds. The community remains divided, with some analysts and long-term bulls highlighting potential structural tailwinds from domestic grid expansion and infrastructure demand, while others express concerns over the ongoing POSCO deal negotiations and short-term technical selling pressure.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors react to its role as a key U.S.-based, vertically integrated rare earth producer amidst intensified geopolitical tensions and national security concerns. Community discussion is heavily focused on the company's long-term supply chain importance, its recent appearance on a major television segment, and the broader implications of U.S. government policy supporting domestic critical mineral independence.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing heightened community focus due to its strategic partnership with NVIDIA and its role in quantum-enabled precision timing solutions, which investors view as a critical, undervalued play in the quantum sector. While discussions are buzzing about the stock's potential for a short squeeze and its low float compared to peers, many are also debating the technical impact of upcoming share lock-up expirations and volatility patterns.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as a major play in the psychedelic medicine space following a presidential executive order that fast-tracks federal research and access for treatments like psilocybin. The community is actively debating the potential for an FDA approval breakthrough for the company's leading COMP360 candidate, with many investors closely tracking the regulatory tailwinds alongside sentiment from key institutional backers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tudor Investment Corp ET AL Buys Shares of 65,964 Aurinia Pharmaceuticals Inc $AUPH

Tudor Investment Corp ET AL bought a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) (TSE:AUP) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 65,964 shares of the biotechnology company's stock, valued...

Aurinia Pharmaceuticals (NASDAQ:AUPH) Sets New 12-Month High - Here's What Happened

Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 52-Week High - Here's What Happened...

Ritholtz Wealth Management Acquires 174,301 Shares of Aurinia Pharmaceuticals Inc $AUPH

Ritholtz Wealth Management increased its holdings in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) (TSE:AUP) by 206.2% in the fourth quarter, according to its most recent disclosure with...

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of "Hold" by Analysts

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) (TSE:AUP) has earned an average recommendation of "Hold" from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have given a b...

JPMorgan Chase & Co. Grows Stock Holdings in Aurinia Pharmaceuticals Inc $AUPH

JPMorgan Chase & Co. grew its holdings in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) (TSE:AUP) by 21.7% in the third quarter, according to its most recent filing with the Securities...

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it...

<ul class="summary-bullets"><li>Michael Hearne has been appointed Chief Financial Officer, replacing Joe Miller.</li><li>Decision to remove Greenleaf and install Tang as CEO represents a “complete validation” of concerns raised for nearly three years, major shareholder MKT Capital said in a statement.</li><li>The company is looking to initiate a clinical study of Aritinercept for an autoimmune disease in the first half of 2026.&nbsp;</li></ul>Aurinia Pharmaceuticals (AUPH) drew strong retail interest on Monday after naming Kevin Tang as Chief Executive Officer, fueling investor hopes of a “new positive era” for the company.<a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> was up more than 6% at the time of writing.Tang, who is also the Chair of the Board, will replace Peter Greenleaf, who has been the company’s CEO for the past 7 years. Tang, an industry veteran, previously served as Chairman of La Jolla Pharmaceutical Company from 2014 through its acquisition by Innoviva in 2022.In 2013, Tang founded Odonate Therapeutics and served as its Chairman and CEO through 2022. Mr. Tang also co-founded Ardea Biosciences in 2006 and Heron Therapeutics in 2009. From 2009 through its acquisition by Keenova Therapeutics in 2010, Tang served as Director of Penwest Pharmaceuticals Co.Among other changes, Michael Hearne has been appointed Chief Financial Officer, replacing Joe Miller. Meanwhile, Ryan Cole was appointed as Chief Operating Officer, and Thomas Wei took over as Chief Scientific Officer.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment flipped to ‘bullish’ from ‘bearish,’ amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/AUPH_jpg_4ef07ce8ea.webp" alt="AUPH.jpg">One user speculated on the implications of the management change for the company, akin to the potential for it to go private.<stembedurl>https://stocktwits.com/US_Bull/message/648264487</stembedurl>Another user said, “Hopefully this starts the beginning of a new positive era”.<stembedurl>https://stocktwits.com/cjohoya/message/648275231</stembedurl>In 2021, Aurinia Pharmaceuticals launched LUPKYNIS, an FDA-approved oral treatment for adults with active Lupus Nephritis. The company also plans to begin a clinical study of Aritinercept for an autoimmune disease in the first half of 2026. Aurinia reported its first full-year profit in December 2024.<h2 class="st-heading-2">MKT’s Statement On Management Changes</h2>MKT Capital, a major long-term shareholder of Aurinia, issued a statement following the appointment of Kevin Tang as CEO.“Today marks a watershed moment for Aurinia shareholders. Since 2019, we have tirelessly advocated for accountability, disciplined capital allocation, and genuine alignment between management and the true owners of this Company – its shareholders. The Board’s decision to remove CEO Peter Greenleaf and his executive team, and to install Chair Kevin Tang as CEO, represents a complete validation of the concerns we have raised for nearly three years,” said Antoine Khalife, Founder of MKT Capital.In April 2025, MKT Capital announced its intention to withhold support for Greenleaf at the 2025 Annual General Meeting.Year-to-date, the stock has fallen 6.5%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nvda-stock-200-dma-rebound-ai-factories-deal/cZ3mgN2RI0Z">NVDA Stock Rebounds But Remains Below Key Support For Second Session: Retail Sees Massive Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aurinia Pharmaceuticals logo is seen displayed on a smartphone screen

AUPH Stock Rallies After CEO Shake-Up: Retail Bulls Bet On Turnaround

Aurinia Pharmaceuticals named Kevin Tang as its Chief Executive Officer, replacing Peter Greenleaf.

Equity

Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning

Aurinia Pharmaceuticals shares are trading higher Monday after announcing a leadership transition seen as a sign of continuity and strategy.read more...

Aurinia Announces Management Transition

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced today that Kevin Tang, Aurinias Chair of the Board, will succeed Peter Greenleaf as Chief Executive Officer. Peter will continue as a consultant...

Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Below 200-Day Moving Average - Here's What Happened

Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Crosses Below 200-Day Moving Average - Time to Sell...

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Bullish continuation

Sideways chop

Fade lower

Full reversal

The market rebounded fast this week — what’s your call for next week?

Stocktwits

Stocktwits Polls

Traders are fiercely debating the probability of a company sale following leadership changes and strategic shifts in the coming months.

Short-term traders are frustrated by the stock oscillating around the 16 dollar price point, frequently employing rinse-and-repeat swing tactics.

Market participants are eyeing significant short interest and upcoming volume spikes, betting on a forced rally to smoke out bearish positions.

Current Price	$16.05
Prev Close	$15.83
Open	$16.07
Dividend Yield	0.00%
50-Day Moving Average	$14.75
Beta	0.86
Avg. Volume	1.21M
PE Ratio	7.73

52-Week High	$16.54
52-Week Low	$7.29
Market Capitalization	$2.13B
EPS (Annual)	$2.07
Price to Book	3.65
Revenue Per Employee	$2.21M

AUPH
Aurinia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AUPH News

AUPHAurinia Pharmaceuticals Inc